GLP-1 medications reduce overall food intake, and many patients naturally reduce refined carbohydrate consumption as appetite suppression shifts food preferences toward higher-protein, lower-sugar options
A total of 120 people with type 2 diabetes (HbA 1c 48 mmol/mol [6.5%]) and at high risk of CVD (age 50 years) were randomised into four parallel groups ( n =30 in each group) for 32 weeks: 1.0 mg semaglutide (open label)
However, it may not seem too drastic since you are only switching medication and not stopping use completely
Together with our comprehensive weight management strategies, our goal is to assist you in reaching and keeping a healthier weight
Recent research suggests pleiotropic therapeutic endpoints, such as the lowered risk of cardiovascular complications in vulnerable populations [1, 2]
In the single-dose trial, semaglutide exposure was highest when co-formulated with 300 mg SNAC